Guolin Zhang Founder & CEO, OmicSkyBio LLC | Mass Spectrometry & AI Multi-Omics

Founder & CEO

OmicSkyBio

Jan 2026 - Current (10 months)

Founded and lead OmicSkyBio, a biotechnology service company focused on advanced mass spectrometry and AI-enabled multi-omics solutions for biotech, pharmaceutical, and academic research programs.

OmicSkyBio delivers integrated LC–MS based bioanalysis and multi-omics solutions spanning proteomics, metabolomics, lipidomics, secretomics, extracellular vesicle analysis, targeted biomarker assays, antibody characterization, peptide mapping, intact mass analysis, and biological data interpretation. The company helps clients translate complex biological questions into practical analytical workflows, high-quality datasets, and decision-ready scientific insights.

K

Scientific Consultant – LC–MS Bioanalysis & Biomarkers

Keystone Bioanalytical

Jul 2025 - Current (1 year 4 months)

Joined Keystone as a full-time scientist during a mutual trial period to support regulated LC–MS/MS bioanalysis in a GLP/GCP-compliant CRO serving large pharma, biotech, and academic sponsors.

Strengthened and applied regulated bioanalysis expertise (GLP, GCP, GCLP) across PK/PD, biomarker, and drug-metabolism studies, from assay concept through data review.

Contributed to development of LC–MS–based assays across multiple modalities, including small-molecule drugs, oligonucleotides (ASO) (blood protein binding), and protein therapeutics, using Shimadzu high-flow LC and SCIEX triple-quadrupole platforms alongside DNA/RNA analytical systems.

Involved in, and where appropriate co-led, development of assays for

S

Principal Scientist

Sensei Biotherapeutics

Apr 2022 - Nov 2024 (2 years 8 months)

Built and lead a high-performing bioanalytical / MS–omics function, recruiting and mentoring scientists and establishing a specialized LC-MS/omics group as a core capability for the organization.

Established a state-of-the-art MS/omics lab and analytical pipelines (DDA, DIA, PRM, intact mass, peptide mapping, multi-omics), centralizing key bioanalytical activities for drug characterization, biomarker validation, MOA studies, and QC of monoclonal and bispecific antibodies. Reduced vendor reliance and optimized workflows and budgets to increase efficiency and accelerate innovation.

Led multi-omics MOA studies (proteomics, phosphoproteomics, secretome, surfaceome, EV-omics, transcriptomics, metabolomics), generating actio

Senior Scientist

mProbe Inc

Mar 2020 - Apr 2022 (2 years 2 months)

Established and led the discovery proteomics capability at the Rockville site, setting technical standards, mentoring scientists, and driving cross-site technical training to improve consistency and efficiency.

Developed a robust quantitative clinical proteomics platform integrating UHPLC–DDA–MS, UHPLC–DIA–MS, and UHPLC–PRM–MS for biomarker discovery and validation across biofluids (serum, plasma, platelets, urine) and solid tissues (FFPE, fresh frozen tumors).

Led early-stage diagnostic product research and clinical service projects by delivering strategic multi-omics insights, including biofluid proteomics, peptidomics, metabolomics, and FFPE tumor tissue proteomics.

Contributed to building and training on

Research Scientist

Moffitt Cancer Center

May 2011 - Feb 2020 (8 years 10 months)

Proteomics, phosphoproteomics, and activity‐based proteomics for multi-project blood cancer studies as part of the Incyte–Moffitt Cancer Center multi-year oncology alliance, supporting identification of effective SHP2 ± JAK2 inhibition in myeloproliferative neoplasms and synergistic PIMi + BETi combinations in myeloid leukemia (Am J Hematol. 2024; Clin Cancer Res. 2023).

SEPTM (Sequential Enrichment of Post-Translational Modifications) Proteomics for Cancer Resistance (PLoS Comput Biol. 2023): Developed a proteomics pipeline to investigate post-translational modifications, uncovering points of crosstalks among signal pathways, resistance mechanisms and therapeutic targets.

Multi-omics proteogenomics in lung squamous ce

Visiting Scientist

MIT

Jul 2009 - Aug 2009 (2 months)

Extensive training in advanced phosphoproteomics technology.
In-depth theoretical and practical expertise in quantitative phosphoproteomics.
Developed and optimized protocols for phosphopeptide separation using iTRAQ and IMAC methodologies.

H

Postdoctoral Fellow

H Lee Moffitt Cancer Center Research Institute

Oct 2007 - Apr 2011 (3 years 7 months)

Mass Spectrometry Mapping of EGFR Phosphorylation Applied mass spectrometry to quantify EGFR phosphorylation in relation to oncogenic mutations and TKI sensitivity, revealing mutation-specific impacts on drug response. (J Proteome Res. 2011)

Cancer Therapeutic Response Database Developed the Quantitative Assay Database (QuAD) (http://proteome.moffitt.org/QUAD/), a resource for analyzing cancer therapeutic responses through quantitative pathway profiling. (Proteomics Clin Appl. 2011)

EGFR as a Target in Lung Cancer Reviewed the significance of EGFR mutations and resistance mechanisms to EGFR-TKIs in NSCLC, emphasiz

Guolin Zhang

About

Detail

Timeline

Résumé

Guolin Zhang

About

Detail

Behavioral traits